New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2013
07:23 EDTTRIBTrinity Biotech reports Q4 EPS 21c, consensus 21c
Reports Q4 revenue $20.8M, consensus $21.84M. The company is making significant progress in the development of its new cardiac point of care tests. With regard to Troponin I, the company is currently focusing on completing development of the test with a view to meeting the new FDA guidelines for Troponin I. The company is also preparing for the forthcoming CE marking trials which will take place at multiple sites in Europe, commencing in Q2. CE marking remains on target for Q4 after which sales in the European market will commence. FDA trials are due to commence in Q3 with submission to the FDA scheduled for 1Q14.
News For TRIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
07:42 EDTTRIBTrinity Biotech recent weakness an 'excellent' opportunity, says Stephens
Stephens attributes Trinity Biotech's Q2 miss to HIV and Lyme Disease testing, but said their "lumpiness" is not unexpected and that the company still has organic growth acceleration, margin expansion and the Troponin/BNP submission ahead of it. Stephens sees the recent weakness in the stock as an "excellent" opportunity and maintains its Overweight rating and $22 price target on Trinity shares.
July 28, 2015
09:33 EDTTRIBTrinity Biotech Meritas Troponin ACS study now open
Subscribe for More Information
09:32 EDTTRIBTrinity Biotech reports Q2 EPS 10c, consensus 14c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use